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Abstract
Background
Infections with multidrug-resistant (MDR) microorganisms are an increasing threat to hospi-
talized patients. Although rapid typing of MDRmicroorganisms is required to apply targeted
prevention measures, technical barriers often prevent this. We aimed to assess whether
extended-spectrum beta-lactamase (ESBL)-producing Klebsiella species are transmitted
between patients and whether routine, rapid typing is needed.
Methods
For 43 months, the clonality of all ESBL-producing Klebsiella isolates from patients admitted
to Erasmus MC University Medical Center in Rotterdam, the Netherlands was assessed
with Raman spectroscopy. A cluster was defined as n2 patients who had identical iso-
lates. Primary patients were the first patients in each cluster. Secondary patients were
those identified with an isolate clonally related to the isolate of the primary patient.
Results
Isolates from 132 patients were analyzed. We identified 17 clusters, with 17 primary and 56
secondary patients. Fifty-nine patients had a unique isolate. Patients (n = 15) in four out of
the 17 clusters were epidemiologically related. Ten of these 15 patients developed an
infection.
Conclusions
Clonal outbreaks of ESBL-producing Klebsiella species were detected in our hospital. Theo-
retically, after Raman spectroscopy had detected a cluster of n2, six infections in second-
ary patients could have been prevented. These findings demonstrate that spread of ESBL-
producing Klebsiella species occurs, even in a non-outbreak setting, and underscore the
need for routine rapid typing of these MDR bacteria.
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Introduction
Infections with multidrug-resistant (MDR) microorganisms are an increasing threat to hospi-
talized patients, leading to high morbidity and mortality because of ineffective antibiotic treat-
ment [1, 2]. In general, carriage of antimicrobial resistant organisms occurs de novo by
induction and selection during therapy (endogenous sources) or by transmission of already
resistant organisms (exogenous sources). In healthcare settings transmission occurs either
direct—patient to patient—or indirect via surrounding reservoirs or sources in the environ-
ment.[3] Exogenous infections can be prevented using measures aiming at preventing trans-
mission. Nevertheless, Gram-negative bacteria producing beta-lactamase enzymes such as
extended-spectrum beta-lactamase (ESBL) or carbapenemases are currently of major concern.
These resistant bacteria are a major cause of healthcare-related infections, especially in patients
with a prolonged hospital stay [4].
Although the spread of ESBL-producing Klebsiella spp. has not yet been elucidated, current
data indicate that they are mainly polyclonal with some small clusters in the hospital [5, 6].
However, if these small clusters go unnoticed and/or appropriate infection control measures
are not taken, they may result in large hospital-wide outbreaks [7]. Because the prevalence of
ESBL-producing Klebsiella spp. is increasing worldwide, hospitals must remain vigilant [4, 8].
It should however be noted that the prevalence differs among patient groups, clinical and geo-
graphic settings [4, 8].
Rapid typing of MDR microorganisms can be of great support to demonstrate spread of
related microorganisms. As a result targeted infection prevention measures are to be applied to
stop transmission. Although MDR bacteria can be easily detected in a routine setting using
proper indicator antibiotics combined with confirmation assays, rapid typing of these isolates
is often not routinely performed. This is mainly due to technical barriers: most typing tech-
niques are time consuming and laborious and therefore difficult to implement in routine diag-
nostics. Raman spectroscopy is a rapid technology that is used for whole organism
fingerprinting and is applied in microbiological laboratories. This technique provides highly
information-rich spectra which are required for maximum discriminatory power to distinguish
unrelated microorganisms—which is required in outbreak management [9–11].
In this study, we applied this rapid typing technique to all ESBL-producing Klebsiella spp.
that were identified in our hospital in the Netherlands for 43 months, in order to answer the
following questions: first, are ESBL-producing Klebsiella spp. transmitted between patients?
Second, is routine, rapid typing needed in an apparently non-outbreak setting?
Materials and Methods
Ethics statement
Screening was performed as part of the infection control strategy using non-invasive sampling.
The microbiological and epidemiological analyses were in first instance performed to develop
new strategies for infection control. Also, according to the Dutch regulation for research with
human subjects, neither medical nor ethical approval was required to conduct the study since
the data were retrospectively recorded. However, we received approval from the medical ethics
research committee of the Erasmus University Medical Center (Erasmus MC) in Rotterdam,
the Netherlands to conduct this study (MEC-2011-085). The existing data from the electronic
medical records could not be recorded anonymously as the patient name is always present.
Before data analyses however, the opt-out list available at our department was consulted and
patient names were removed from the dataset by A.F. Voor in ‘t holt. The authors had no direct
interaction with the patients and no new patient data were collected during the study period.
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Population
This study was conducted at the Erasmus MC in Rotterdam, the Netherlands. This is a
1,320-bed university hospital, with 97 beds in the adult or pediatric intensive care unit (ICU)
(Erasmus MC, 2012). All medical specialties are available. Table 1 presents the number of hos-
pital admissions from 1 January 2010 until 1 August 2013, the number of patients identified
with Klebsiella spp.—susceptible and ESBL-producing isolates—and the number of patients
who were included in the current study.
Study Design and Data Collection
We included patients of all departments with a microbiologically confirmed ESBL-producing
K. pneumoniae or K. oxytoca between 1 January 2010 and 1 August 2013. After detection, all
patients were immediately managed in contact isolation and placed in single-occupancy
rooms. Contact isolation included the use of gloves and gowns, and disinfection of hands and
wrists with hand alcohol when entering and leaving the room. No active surveillance and/or
contact investigation were carried out. Isolates were cultured from clinical samples, either
because of 1) assumed infection or 2) surveillance purposes in the ICU and hematology depart-
ments—patients receiving selective digestive tract decontamination are routinely tested for the
presence of (resistant) Gram-negative bacteria twice weekly. This study consisted of two study
periods. During study period I, 1 January 2010 until 1 September 2012, isolates were collected
and typed retrospectively. Also, clinical data were collected retrospectively. However, carbape-
nemase-producing isolates were immediately typed after detection at that time. During study
period II (1 September 2012 until 1 August 2013), typing with Raman spectroscopy was per-
formed immediately after detection and clinical data were collected prospectively. In this
report, data from both study periods were combined. Preventive measures were equal in both
periods.
For each first isolate, we recorded patient data and bacteriological data, which were obtained
from electronic patient records. Age of the patient was defined as age at day of detection of the
first ESBL-producing Klebsiella isolate. Mortality was defined as death from any cause within
one year after the day of detection of the first ESBL-producing Klebsiella isolate [12].
To identify healthcare-related infections and the specific type of infection, we used the crite-
ria published by the Centers for Disease Control and Prevention (CDC) [13]. We investigated
microbiological data and medical records of included patients to distinguish colonization from
infection.
Microbiological Analysis
Cultures were performed at the diagnostic laboratory of the department of Medical Microbiol-
ogy and Infectious Diseases (Erasmus MC, Rotterdam, The Netherlands). In study period I,
bacteria were taken from frozen stock cultures kept at -80°C, and were subsequently analyzed
with Raman spectroscopy. In study period II, bacteria were typed with Raman spectroscopy
immediately after the initial culture.
Identification and susceptibility testing for K. pneumoniae and K. oxytoca were performed
using VITEK 2 (bioMérieux, Lyon, France), and results were interpreted according to the
EUCAST clinical breakpoints. ESBL confirmation was performed with either the combination
disk-diffusion test (Rosco Diagnostica, Taastrup, Denmark) or the Etest (bioMérieux, Lyon,
France). K. oxytoca isolates were regarded as ESBL-producing when resistant to ceftazidime
and demonstrating synergy between ceftazidime and clavulanic acid. K. oxytoca isolates were
regarded as hyperproducers of K1 (KOXY) chromosomal beta-lactamase if they showed resis-
tance to cefuroxime, piperacillin-tazobactam and aztreonam, borderline resistance to
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cefotaxime and cefepime, but remained susceptible to ceftazidime [14]. Presence of carbapene-
mases was confirmed using real-time PCR for blaIMP, blaKPC, blaNDM, blaOXA-48, and blaVIM
genes [15].
Clonal Relatedness
Clonal relatedness was investigated with Raman spectroscopy using SpectraCellRA analysis
(SCRA). Cultures, sample preparation, and SCRAmeasurements were performed according to
the operators manual (version 1.7) [16]. Analyses and calculations were performed as described
previously [17]. A cluster was defined as n2 patients who had identical isolates as indicated
with Raman spectroscopic analysis. A distinction was made between primary and secondary
patients, and patients with a unique isolate. A primary patient was defined as the first patient
in time in a cluster. Secondary patients were all subsequent patients who had a proven clonal
relationship with the primary patient. Unique was defined as patients with a non-cluster iso-
late. When analyzing, data from primary patients and from patients with a unique isolate were
combined since they were both the first patient in time with a certain type. The only difference
was that primary patients generated secondary patients, and patients with a unique isolate did
not.
Spatial Analysis
To investigate if patients identified in Raman spectroscopic clusters were epidemiologically
related, four different definitions of epidemiological relatedness were created from highest to
lowest likelihood (Table 2).
Statistical Analysis
We calculated the transmission index (TI) to analyze the transmission dynamics using two dif-
ferent formulas. Firstly, it was calculated as the number of secondary patients divided by the
number of primary patients and the number of patients with a unique isolate—with the results
of Raman spectroscopy. Secondly, as the number of secondary patients who were epidemiolog-
ically related to the primary patient (definitions ‘definite’ and ‘probable’ combined, Table 2)
divided by the number of primary patients and the number of patients with a unique isolate.
Table 1. Study characteristics.
2010 2011 2012 2013a
No. of hospital admissions 40,626 41,773 41,001 21.893
No. of clinical admission days 292.209 288.799 299.736 n.a.
Klebsiella pneumoniaeb 774 677 619 320
ESBL-producing K. pneumoniaec 54 (40) 47 (10) 62 (48) 34 (25)
ESBL-rate per 1000 hospital admissions 1,33 1,13 1,51 1,55
Klebsiella oxytocab 370 338 351 161
ESBL-producing K. oxytocac 7 (0) 5 (3) 15 (5) 3 (1)
ESBL-rate per 1000 hospital admissions 0,17 0,12 0,37 0,14
Abbreviations: n.a., not available, no., number.
a1 January until 1 August 2013;
bOne per patient;
cBetween brackets: number of patients included in current study
doi:10.1371/journal.pone.0136135.t001
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Basic patient characteristics (e.g. age, gender, death from any cause within one year after
positive culture) were analyzed as percentages and means using Microsoft Excel 2010.
Results
Identification and characteristics of included patients
For the period from 1 January 2010 until 1 August 2013 we included 132 patients with an
ESBL-producing Klebsiella isolate (Table 3, Fig 1). ESBL-producing K. pneumoniae was cul-
tured in 123 patients and ESBL-producing K. oxytoca was cultured in nine patients (Table 3).
Ninety isolates were obtained from clinical samples, and 42 isolates were obtained from surveil-
lance cultures. In total, 17 clusters were identified with Raman spectroscopy, comprising 73
patients (cluster size ranging from two to ten patients), and 59 patients were identified with a
unique isolate. Among the 73 patients with a cluster isolate, we identified 17 primary patients,
and 56 secondary patients (Table 3). Eighty-six out of 132 patients (65.2%) developed an infec-
tion with an ESBL-producing Klebsiella spp. (Table 3). Fifty-one out of 17 primary plus 59
unique patients (67.1%) and 35 out of 56 secondary patients (62.5%) developed or had an
infection with the ESBL-producing Klebsiella spp.
Eight patients were identified with an ESBL-producing K. pneumoniae isolate that was also
resistant to imipenem and/or meropenem and three patients with an ESBL-producing K. pneu-
moniae isolate intermediately susceptible to imipenem and meropenem. The blaKPC gene was
detected in six out of these 11 patients, the blaOXA-48 gene was demonstrated in isolates of three
patients and the blaNDM gene was present in isolates of two patients. According to Raman spec-
troscopic analyses, seven out of these 11 patients had a unique isolate. In cluster 15 (n = 2),
both patients had a KPC-producing isolate. In cluster ten (n = 10), two patients had an NDM-
producing isolate.
Clinical Epidemiology
From all 132 patients with an ESBL-producing Klebsiella spp. isolate, 130 were residents of the
Netherlands. The median age of these 132 patients was 57.4; 58.3 for primary patients plus
patients with a unique isolate (n = 17 + n = 59) and 54.8 for secondary patients (n = 56). Two
clusters (cluster 6 and 11) consisted of newborns only. The overall mortality rate one year after
detection of the bacteria was 17.4% (n = 23), consisting of three primary and nine secondary
patients, and 11 patients with a unique isolate. Overall male percentage was 62.1%; 61.8% in
primary patients plus patients with a unique isolate and 62.5% in secondary patients. Twenty-
six patients (19.7%) were organ transplant recipients; three primary and eight secondary
Table 2. Definitions of epidemiological relatedness.
Deﬁnitions
Deﬁnite Probable Possible Impossible
Same patient room yes yes No no
Same department yes yes Yes no
Same period yes maybea maybeb maybec
aSame patient room within 3 months after primary patient has left;
bSame department within 3 months after primary patient has left;
cSame period but not the same department or patient room
doi:10.1371/journal.pone.0136135.t002
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patients, and 15 patients with a unique isolate. The majority of patients received a kidney allo-
graft (n = 22). Basic patient characteristics are displayed in Table 4.
The most frequent specimen containing ESBL-producing Klebsiella spp. cultures for all
patients was urine (45.5%), followed by rectum samples (21.2%). In primary patients plus
patients with a unique isolate, 73.0% of patients who had a positive urine sample developed or
had an infection, compared with 47.8% of secondary patients (P value 0.049). Twenty-three
percent of primary patients who had a positive rectum sample developed or had an infection,
compared with 53.3% of secondary patients (P value 0.102).
Spatial Analysis
From the 132 patients, 95 were admitted to the hospital to 36 different departments. Thirty-
seven patients were not admitted when the ESBL-producing Klebsiella isolate was detected.
Also, 31 patients (23.5%) were admitted to either the ICU or the hematology department.
Patients in cluster 6 (n = 5) and 11 (n = 2) were, according to our definitions, definitely
related as patients were related in time and place (Fig 2). Cluster 6 and 11 both consisted of
newborns infected (n = 3) or colonized (n = 4) with K. oxytoca bacteria (Table 5). Patients in
cluster 13 (n = 5) and 17 (n = 3) were probably related. In six clusters (cluster 3, 4, 5, 8, 10 and
16) a more diverse picture of epidemiological relatedness was found (Table 5, Fig 2). Patients
in cluster one (n = 2), two (n = 4), seven (n = 3), nine (n = 2), 12 (n = 4), 14 (n = 3) and 15
(n = 2) could not be related to each other in time and place: transmission in the hospital was
Table 3. Characteristics of clusters and unique isolates as defined with Raman spectroscopy, January 2010 until August 2013.
Total no. of patients No. of primary patientsa No. of secondary patients
Infection Colonization Infection Colonization
Total 132 51 25 35 21
K. pneumoniae 123 50 22 33 18
K. oxytoca 9 1 3 2 3
Cluster 1 2 0 1 1 0
Cluster 2 4 1 0 0 3
Cluster 3 9 1 0 5 3
Cluster 4 10 0 1 8 1
Cluster 5 5 0 1 4 0
Cluster 6 5 0 1 2 2
Cluster 7 3 1 0 1 1
Cluster 8 3 0 1 1 1
Cluster 9 2 0 1 1 0
Cluster 10 10 1 0 5 4
Cluster 11 2 0 1 1 0
Cluster 12 2 0 1 1 0
Cluster 13 5 1 0 2 2
Cluster 14 3 1 0 2 0
Cluster 15 2 1 0 0 1
Cluster 16 3 1 0 1 1
Cluster 17 3 0 1 0 2
Unique isolates 59 43 16 n.a. n.a.
Abbreviations: n.a., not applicable, no., number.
aIncluding patients with a unique isolate
doi:10.1371/journal.pone.0136135.t003
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Fig 1. Distribution of patients identified with an ESBL-producing Klebsiella spp. (n = 132), January 2010 until August 2013. Black = primary patients
(n = 17); the first patient in time in a cluster, identified with Raman spectroscopy. Grey = secondary patients (n = 56); all subsequent patients who had a
proven clonal relationship with the primary patient. Light grey = patients with a unique isolate (n = 59).
doi:10.1371/journal.pone.0136135.g001
Table 4. Clinical characteristics of patients infected or colonized with ESBL-producingKlebsiella spp. and clinical characteristics of primary and
secondary patients.
Variables No. of patients (%) No. of patients (%)
Infection (n = 86) Colonization (n = 46) Primaryb (n = 76) Secondary (n = 56)
Gender, male 61 (70.9) 21 (45.7) 47 (61.8) 35 (62.5)
Age, mean years (SD) 53.4 (24.0) 42.9 (29.7) 52.3 (23.4) 46.3 (30.1)
COPD 6 (7.0) 1 (2.2) 5 (6.6) 2 (3.6)
1-year mortalitya 18 (20.9) 5 (10.9) 14 (18.4) 9 (16.1)
Organ transplantation 17 (19.8) 9 (19.6) 18 (23.7) 8 (14.3)
No. of primary patientsb 51 (59.3) 25 (54.3) n.a. n.a.
No. of patients who had an infection n.a. n.a. 51 (67.1) 35 (62.5)
Abbreviations: COPD, chronic obstructive pulmonary disease, SD, standard deviation, no., number, n.a., not applicable.
aDeath from any cause within one year after the ﬁrst positive culture;
bIncluding patients with a unique isolate
doi:10.1371/journal.pone.0136135.t004
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Fig 2. Epidemiological relatedness of patients in the 17 clusters. Y-axis: number of patients, x-axis: cluster number. Black = definite, grey = probable,
wide downward diagonal lines = possible, white = impossible.
doi:10.1371/journal.pone.0136135.g002
Table 5. The number of infected and colonized patients in the eight clusters identified with Raman spectroscopy with a definite or probable epide-
miological relationship.
Cluster no. Deﬁnite Probable
Infection Colonization Infection Colonization
Prim Sec Prim Sec
Cluster 3 0 0 0 1 1 0
Cluster 4 0 0 0 0 1 1
Cluster 5 0 0 0 0 2 0
Cluster 6 0 2 3 0 0 0
Cluster 8 0 0 0 0 1 1
Cluster 11 0 1 1 0 0 0
Cluster 13 0 0 0 1 2 2
Cluster 17 0 0 0 0 0 3
Abbreviations: no., number; prim, primary patients including patients with a unique isolate; sec, secondary patients. Epidemiological relatedness is
presented as number of patients.
doi:10.1371/journal.pone.0136135.t005
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impossible according to the information in the medical records of the patients and our defini-
tions (Fig 2).
When using the results of Raman spectroscopy, the transmission index was 0.74 (56 divided
by 17 plus 59; definition 1). When dividing epidemiologically related secondary patients in
clusters by all primary patients, the transmission index declined to 0.30 (23 divided by 17 plus
59; definition 2).
Discussion
Summary of Evidence
There are many ways of preventing antibiotic resistance, and especially the spread of antibiotic-
resistant bacteria can be prevented in many different ways. A powerful policy is to prevent trans-
mission of these resistant bacteria from patient to patient, the success of which depends on the
speed and accuracy of the typing method used for early identification of related clusters. Rapid
and accurate typing allows targeted infection control measures to be applied immediately,
thereby preventing morbidity and mortality among patients and reducing hospital costs [18].
In the present study, we performed an in-depth analysis of the epidemiology of ESBL-pro-
ducing Klebsiella spp. in a large university hospital using clinical samples and screening cul-
tures over a 43-month period. Our results demonstrate that clonal outbreaks with ESBL-
producing Klebsiella spp., as confirmed epidemiologically and by Raman spectroscopy, defi-
nitely occurred in our hospital and should have been prevented. In theory, as soon as clonality
had been demonstrated using Raman spectroscopy (n2), six out of ten infections in seven
different clusters could have been prevented by implementing immediate additional infection
control measures. These additional infection control measures include immediate disinfection
of the patient rooms and sanitation involved and a contact investigation among roommates.
The contact investigation is performed from the first admission date of the primary patient
until the date of contact isolation or discharge of the last secondary patient. The possible
(NDM) and impossible (KPC) transmissions of carbapenemase-producing Klebsiella spp. in
cluster 10 and cluster 15 were noted with typing at the time of detection. Additional screening
of contact patients was performed, which did not reveal other colonized patients. Previous
reports on ESBL-producing Klebsiella spp. have shown similar results, although some studies
have identified large clusters [19]. However, these studies often did not investigate whether
patients in clusters—identified by molecular analysis—were also epidemiologically related
[19].
Due to the retrospective nature of our analysis, our results represent merely the tip of the
iceberg. We hypothesize that if patients had been routinely screened for MDR bacteria upon
admission, during admission, upon discharge and/or after the finding of a primary case, we
would have found more and larger clusters in which patients were epidemiologically related.
The fact that we were not able to define relatedness in all secondary cases was presumably due
in part to unidentified carriers (missed cases) and transmission. A possible additional theoreti-
cal explanation of secondary cases is community spread of these type of bacteria, as carriage in
the community has been reported in the literature and is of rising concern. However, in the
Netherlands spread in the community has not been reported so far [20].
The transmission index was 0.74. When we used epidemiological relatedness as a criterion
for secondary patients, the transmission index decreased to 0.30. However, the R0 could not be
calculated as each patient identified with an ESBL-producing Klebsiella spp. isolate was nursed
in contact isolation and placed in a single-occupancy room immediately after detection. At
that moment it was not clear whether this patient was a primary or a secondary patient. These
prompt measures may have kept the transmission index low.
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Limitations
Our study has a number of limitations. First, patients were not routinely cultured for carrying
multi-resistant Enterobacteriaceae at admission or discharge during the study periods in our
hospital and we were not able to include all the carriers identified in our hospital (Table 1). The
presence of unidentified carriers therefore cannot be ruled out, and we may have underesti-
mated the number of affected patients. Second, the surveillance cultures in our dataset were
only obtained from ICU and hematology patients while the remaining cultures were obtained
from clinical samples. Third, in seven of the 17 clusters identified using Raman spectroscopy
no epidemiological relatedness between patients was found. This may be due to low numbers
of cultures—thus missing cases—and/or to our definition of epidemiological relatedness that
may have been too strict (Table 2). Since contamination of the environment as a source needs
to be taken into consideration when studying transmission, we chose a 3-month window dur-
ing which we still considered transmission to be possible (Table 2) [21, 22]. Unfortunately, nei-
ther nationwide guidelines nor even the CDC provide a definition of epidemiological
relatedness. Finally, we did not include the identification of the specific ESBL genes (e.g.
blaCTX-M, blaSHV, blaTEM) and plasmid types in our analysis of the 132 isolates. Therefore,
transmission between different strains of plasmids carrying ESBL genes cannot be ruled out.
Conclusion and Clinical Implication
In summary, as transmission occurred during the entire study period and throughout the
entire hospital, there is an urgent need for instant typing to detect and subsequently prevent
the spread of ESBL-producing Klebsiella spp. We conclude that typing should continuously be
performed, also in an apparent non-outbreak situation. In order to relate those patients who
have clonally clustered isolates, it is important to actively screen contact patients for carriage of
ESBL-producing Klebsiella spp. These recommendations are similar to those given in previous
investigations and in the recent Dutch MDRO guideline [19, 23–26]. A rapid typing method
that is easy to implement and that can be used for the early identification of clusters is Raman
spectroscopy. Through the implementation of immediate infection-prevention strategies, those
small outbreaks identified early on can be stopped and further transmission can be prevented.
However, further research is needed to investigate the presence of ESBL-producing Klebsiella
spp. and their transmission dynamics in other hospital settings. This will give further insight in
the transmission magnitude of Klebsiella spp. in the hospital.
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